Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

by Mitsunaga, S, Ikeda, M, Shimizu, S, Ohno, I, Furuse, J, Inagaki, M, Higashi, S, Kato, H, Terao, K, Ochiai, A
Published 2013

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

by Ikeda, M., Shimizu, S., Sato, T., Morimoto, M., Kojima, Y., Inaba, Y., Hagihara, A., Kudo, M., Nakamori, S., Kaneko, S., Sugimoto, R., Tahara, T., Ohmura, T., Yasui, K., Sato, K., Ishii, H., Furuse, J., Okusaka, T.
Published 2016

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer†

by Ueno, M., Okusaka, T., Omuro, Y., Isayama, H., Fukutomi, A., Ikeda, M., Mizuno, N., Fukuzawa, K., Furukawa, M., Iguchi, H., Sugimori, K., Furuse, J., Shimada, K., Ioka, T., Nakamori, S., Baba, H., Komatsu, Y., Takeuchi, M., Hyodo, I., Boku, N.
Published 2016

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

by Lencioni, R, Kudo, M, Ye, S-L, Bronowicki, J-P, Chen, X-P, Dagher, L, Furuse, J, Geschwind, J F, de Guevara, L Ladrón, Papandreou, C, Takayama, T, Yoon, S K, Nakajima, K, Lehr, R, Heldner, S, Sanyal, A J
Published 2014

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

by Matsuyama, Masato, Ishii, H., Furuse, J., Ohkawa, S., Maguchi, H., Mizuno, N., Yamaguchi, T., Ioka, T., Ajiki, T., Ikeda, M., Hakamada, K., Yamamoto, M., Yamaue, H., Eguchi, K., Ichikawa, W., Miyazaki, M., Ohashi, Y., Sasaki, Y.
Published 2014